Target intelligence / Profile preview

AMPA-type glutamate receptor and Kainate-type glutamate receptor (AMPA receptor (AMPAR), Kainate receptor (KAR))

Target
AMPA receptor (AMPAR), Kainate receptor (KAR)
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor, Ionotropic glutamate receptor
01

Overview

AMPA and kainate glutamate receptors are two distinct classes of ionotropic glutamate receptors that function as tetrameric ligand-gated ion channels in the central nervous system. These receptors mediate rapid excitatory synaptic transmission by allowing the flux of sodium and, in specific subunit compositions, calcium ions upon activation by glutamate. AMPA receptors are responsible for the majority of fast postsynaptic excitatory transmission and are critical to basic neural signaling, learning, and memory. Kainate receptors, while less prevalent, modulate both pre- and postsynaptic aspects of neurotransmission, contribute to synaptic plasticity, and are implicated in numerous neurological and psychiatric diseases. Both AMPA and kainate receptors are assembled as tetramers using distinct subunits encoded by the GRIA and GRIK gene families, respectively. Their function can be modulated by endogenous and synthetic ligands, with antagonism showing anti-epileptic potential and positive modulation of kainate receptors being a current topic in experimental therapeutics. Excessive activation of these receptors contributes to excitotoxic neuronal damage seen in stroke, epilepsy, and neurodegeneration.

Other names
AMPA receptorAMPARα-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptorGluA receptorGRIA receptorKainate receptorKARKainic acid receptorGluK receptorGRIK receptorIonotropic glutamate receptors (iGluRs)
02

Mechanism of action

Antagonists block glutamate binding or channel opening, inhibiting excitatory neurotransmission. Positive allosteric modulators prolong activation or prevent desensitization of kainate receptors. Negative allosteric modulators decrease channel activity. Channel blockers block ion conductance after receptor activation. Agonists activate the receptors directly (generally used for research).

03

Biological functions

Signal transduction (mediating glutamatergic synaptic transmission)Fast excitatory neurotransmission (especially AMPA)Synaptic plasticity (learning, memory, long-term potentiation)Modulation of neuronal circuits (especially kainate)Development and maturation of neural networks (especially kainate)
04

Disease associations

Neurodegenerative disease (e.g., Alzheimer's, Huntington's)Epilepsy (especially kainate receptor involvement)SchizophreniaDepressionAnxietyAutism spectrum disordersOther neurological disorders
05

Safety considerations

Excitotoxicity: Excessive activation can cause neuronal damage, implicated in stroke and neurodegenerationSeizures: Overactivation, antagonism, or inappropriate modulation can provoke or exacerbate epileptic activityCognitive effects: Drugs that block these receptors may impair learning or memoryOff-target CNS effects: Due to broad expression in brainPsychiatric effects: Modulation may affect mood or cause psychiatric symptomsLimited therapeutic window for antagonists due to widespread role in synaptic transmission
06

Interacting drugs

Perampanel (non-competitive AMPA receptor antagonist, used in epilepsy)

6 more in the full profile.

07

Biomarkers

Currently, no standardized clinical biomarkers specifically for AMPA or kainate receptor modulation in patient selection or monitoring. Some indirect measures (e.g., gene expression, receptor density via imaging, antisera/antibodies in research) are available.

Beyond the preview

Go deeper on AMPA-type glutamate receptor and Kainate-type glutamate receptor (AMPA receptor (AMPAR), Kainate receptor (KAR)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMPA-type glutamate receptor and Kainate-type glutamate receptor (AMPA receptor (AMPAR), Kainate receptor (KAR)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call